DDB1 and plasma cell myeloma: Nonetheless, the definitive leap for thalidomide and its derivatives was made in proving their efficiency against multiple myeloma and other pathologies [83], and their mechanism of action, which defined the E3 ligase CRBN and the DNA-damage-binding protein 1 (DDB1) as the endogenous targets [84,85,86,87,88].